Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.
Alpha-Fetoprotein, or AFP – normally expressed during development and by liver cancer cells as well – has escaped attack in previous vaccine iterations because the body recognizes it as “self,” said Dr. Yukai He, immunologist at the Medical College of Georgia and Georgia Regents University Cancer Center.
Liver cancer is among the fastest-growing and deadliest cancers in the United States with a 17 percent three-year survival rate. Vaccines help direct the immune system to attack invaders by showing it a representative substance, called an antigen, that the body will recognize as foreign, in this case, AFP for liver cancer.
Read more . . .
The Latest on: Liver cancer
[google_news title=”” keyword=”Liver cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liver cancer
- Novel Blood Biomarkers Show Potential for Early Liver Cancer Diagnosison May 1, 2024 at 5:00 pm
“Liver cancer rates are rapidly increasing, and liver cancer has a high mortality rate, but if we can diagnose it early, therapeutic interventions can be potentially curative,” lead author Xinyuan Zhang, PhD, of the Channing Division of Network Medicin ...
- G1 Therapeutics inks $135M deal with Boston firm for cancer treatmenton April 30, 2024 at 5:00 pm
The biotech is focused on liver cancer and has the rights to develop the molecule in all indications except for certain radioprotectant uses. The deals follows the termination of a previous licensing agreement between G1 and EQRx involving lerociclib.
via Bing News
